Navigation Links
DNA2.0 Launches New Website: Enhanced Design and Free Bioinformatics Tools Demonstrate DNA2.0's Customer Focus
Date:10/17/2008

DNA2.0, the leading synthetic genomics company, announced today a significant redesign of its web site, including a fresh, appealing new interface, a customer-friendly site navigation, a database of published synthetic gene applications and a revamped Bioinformatics Toolbox that provides visitors with a powerful resource for analyzing DNA and protein sequences.

Menlo Park, Calif. (PRWEB) October 17, 2008 -- DNA2.0, the leading synthetic genomics company, announced today a significant redesign of its web site, providing customers with an enhanced experience and demonstrating the company's expansion. The redesign of the site introduced a fresh, appealing new interface, a customer-friendly site navigation, a database of published synthetic gene applications and a revamped Bioinformatics Toolbox that provides visitors with a powerful resource for analyzing DNA and protein sequences.

"The customer focus of our new site mirrors our commitment to innovation and efficiency in providing high-quality gene synthesis," said Dr. Claes Gustafsson, vice president of sales and marketing for DNA2.0. "DNA2.0 is dedicated to being a resource and research partner for the scientific community. By providing an easy-to-use interface and strengthening our Bioinformatics Toolbox, we are renewing our emphasis on customer service."

DNA2.0's Bioinformatics Toolbox:
Already hailed by Genetic Engineering News as "Best of the Web," DNA2.0's Bioinformatics Toolbox provides tools for generating, formatting and analyzing DNA and protein sequences. With an extensive rage of tools designed for such functions as format conversion, sequence analysis, and sequence figures, the Bioinformatics Toolbox puts all the technology and expertise needed for gene design at the fingertips of the user. The Bioinformatics Toolbox is now easier to use than ever, with convenient pop-out boxes for each to
'/>"/>

Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
2. Research Triangle Area Health Care Collaborative Launches Bridges to Excellence(R) Initiative to Improve Quality and Lower Costs
3. Novozymes Launches Enzyme to Reduce Acrylamide in Food
4. Enova Medical Launches Exos Corporation
5. Elekta Launches New Linear Accelerator at 2007 ESTRO to Expand Cancer Treatment Availability
6. Signalifes Dr. Harmison Launches Award-Winning Ambulatory Heart Monitor
7. ThirdBiotech Networking Group Launches
8. BioReliance Launches Next-Generation Genotoxicity Screening Service
9. Midwest Research Institute Launches Center for Biological Safety and Security (CBS2)
10. BioReliance Corporation Launches iNet(TM) for Online Results Tracking of Biological Safety Tests
11. Kingfisher Healthcare Launches Breakthrough Product in Europe

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)...Newswire-FirstCall/ -- Helix BioPharma Corp. (TSX,...that John Docherty, president and chief operating ...h annual Investor Summit on November 10, 2009 at 4... Docherty will provide an overview of the Company,... Topical Interferon Alpha-2b. The slide show port...
(Date:11/6/2009)...PRNewswire-FirstCall/ -- ,, 3Q09 Corporate H...TM) E.U. Marketing Authorization to Astellas Pharm...rcial readiness activities Expanded management te...; and Director, Commercial Operations Appointed B...Committee chairman , Upcoming 2009 Mileston...
(Date:11/6/2009)...Newswire/ -- Intarcia Therapeutics, Inc. delivered...74; continuous delivery of exenatide) program for ...al Diabetes Technology Meeting in San Francisco, C...nh/20050301/SFTU126LOGO ) ,, Continuous Subcu...Plasma Glucose, HbA1c and Reduces Weight in a 28-d...
(Date:11/5/2009)...PRNewswire-FirstCall/ -- GenVec, Inc. (Nasdaq: GN... third quarter ended September 30, 2009. GenVec re...) for the three months ended September 30, 2009 co...are) in the comparable quarter of 2008. For the ni...oss was $14.1 million ($0.15 per share), compared ...
Breaking Biology Technology:Helix BioPharma to Present at Merriman Curhan Ford's Investor Summit 2009 on November 10th 2Helix BioPharma to Present at Merriman Curhan Ford's Investor Summit 2009 on November 10th 3NeurogesX Reports Third Quarter 2009 Results 2NeurogesX Reports Third Quarter 2009 Results 3NeurogesX Reports Third Quarter 2009 Results 4NeurogesX Reports Third Quarter 2009 Results 5NeurogesX Reports Third Quarter 2009 Results 6NeurogesX Reports Third Quarter 2009 Results 7NeurogesX Reports Third Quarter 2009 Results 8NeurogesX Reports Third Quarter 2009 Results 9NeurogesX Reports Third Quarter 2009 Results 10Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 2Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 3Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 4Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 5GenVec Reports Third Quarter 2009 Financial Results 2GenVec Reports Third Quarter 2009 Financial Results 3GenVec Reports Third Quarter 2009 Financial Results 4GenVec Reports Third Quarter 2009 Financial Results 5GenVec Reports Third Quarter 2009 Financial Results 6
...RDAM, The Netherlands, February 18 ,Amsterdam Mole...e field of,human gene therapy, announced today tha...ll year 2008 on Tuesday, February 24, 2009 at 7:00...results, the Company will,conduct a conference cal... for the Netherlands is 0800-949-4166 (toll free)....
...b., Feb. 18 Transgenomic Inc. (OTC Bulletin Board...hat: Transgenomic Inc. Fourth Quarter 2008 Ear...en: Wednesday, February 25, 2009 @ 5:00 p.m. E...vents.asp?id=6 , How: Live over the Intern... address above., , , To access the call via te...
...ES, Feb. 18 The Board of Directors wishes to conf...y 4, 2009 it resolved to file a Form 15 with effec...t require the approval of stockholders but in the ...olders informed the Board is making this Release. ...ompany from its United States Securities and Excha...
Other Biology Technology:AMT to Release Full Year 2008 Results on February 24, 2009 2Webcast Alert: Transgenomic Inc. Announces Fourth Quarter 2008 Earnings Release Conference Call Webcast 2EESTECH Inc - Release From SEC Filing 2EESTECH Inc - Release From SEC Filing 3EESTECH Inc - Release From SEC Filing 4
(Date:11/9/2009)...9, 2009 / b3c newswire / - Today, TNO, a Dutch ...an American organization for contract research and...ned a letter of intent with regard to TNOs dynamic...r of intent proposes a collaboration in which Seve...lization in North America. The TIM systems will be...
(Date:11/9/2009)...stry leaders from around the world will gather in ...lecular Targets and Cancer Therapeutics Internatio...information on important cancer therapies in devel...reat it effectively we need a greater understandin...r level," said Lewis Cantley, Ph.D., director of t...
(Date:11/8/2009)...hers at Purdue University have discovered a new ap...l cord injuries using nano-spheres that could be i..., The synthetic "copolymer micelles" are drug-de... roughly 100 times smaller than the diameter of a ... how to deliver drugs for cancer treatment and oth...
Breaking Biology News(10 mins):TNO and Seventh Wave sign letter of intent on joint preclinical pharmaceutical outsourcing services 2Findings show nanomedicine promising for treating spinal cord injuries 2Findings show nanomedicine promising for treating spinal cord injuries 3InVitria Reports Successful Cell Culture Performance of Zap CHO a Defined and Cost Effective CHO Cell Culture Media Supplement 60242 1InVitria Reports Successful Cell Culture Performance of Zap CHO a Defined and Cost Effective CHO Cell Culture Media Supplement 60242 2NeuroVasx Announces First Case of cPAX Aneurysm Treatment System in Spain 60238 1NeuroVasx Announces First Case of cPAX Aneurysm Treatment System in Spain 60238 2NeuroVasx Announces First Case of cPAX Aneurysm Treatment System in Spain 60238 3Health Partners to Offer Health Insurance Through the Childrens Health Insurance Program 60234 1Health Partners to Offer Health Insurance Through the Childrens Health Insurance Program 60234 2
... When Yadong Wang, a chemist by training, first ve...idn,t know that his peers would have considered hi...cuits use electrical signals often conducted by ne...te between the brain and the rest of the body, he ...ed to repair a broken circuit. The neurotransmitte...
... University of Manchester researchers are recruiti...?commonly known as sciatica ?in the first ever stu...their condition. , Dr Christopher McCarthy and his...n Science need 30 volunteers aged 22-55 who have h...nt and have not had previous spinal surgery. , ...
... Using the latest in high tech tools, researchers ...edictive of chronic lung rejection up to 20 months...patients have the highest mortality rate of organ ...nvestigator and pulmonologist Chris Wendt. Current...splants will fail, and when signs of chronic rejec...
Other Biology News:Dopamine used to prompt nerve tissue to regrow 2Proteins may predict lung transplant rejection 2Proteins may predict lung transplant rejection 3
RosetteSep Anti-Human IgE, 200 ul from StemCell Technologies, Inc.
BAS 2500 Image Analysis System from FUJIFILM Life Science
Bio-imaging Analyzer BAS-1800II from FUJIFILM Life Science
Uniblot accessories from Sigma-Aldrich
Biology Products: